

Resource Summary Report

Generated by [NIF](#) on Sep 18, 2026

Kasumi-2

RRID:CVCL_0590

Type: Cell Line

Proper Citation

RRID:CVCL_0590

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0590

Proper Citation: RRID:CVCL_0590

Description: Cell line Kasumi-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Childhood B acute lymphoblastic leukemia

Defining Citation: [PMID:10739008](#), [PMID:11226526](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:29786757](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31305009](#), [PMID:31978347](#), [PMID:32180206](#), [PMID:35124168](#), [PMID:35354797](#)

Comments: Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Kasumi-2

Synonyms: KASUMI-2, KASUMI2, Kasumi2

Cross References: EFO:EFO_0002224, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2770, BioSample:SAMN03473522, BioSample:SAMN10988450, cancercellines:CVCL_0590, Cell_Model_Passport:SIDM01694, Cosmic:1130249, Cosmic:1524843, DepMap:ACH-000728, DSMZ:ACC-526, DSMZCellDive:ACC-526, GEO:GSM236786, GEO:GSM236822, GEO:GSM887198, GEO:GSM888271, GEO:GSM4254130, GEO:GSM5137720, GEO:GSM5137758, IARC_TP53:28402,

IGRhCellID:Kasumi2, JCRB:JCRB1395, LiGeA:CCLE_042,
PharmacDB:KASUMI2_734_2019, PRIDE:PXD023662, Progenetix:CVCL_0590,
Wikidata:Q54899516

ID: CVCL_0590

Record Creation Time: 20220427T220657+0000

Record Last Update: 20260913T004644+0000

Ratings and Alerts

No rating or validation information has been found for Kasumi-2.

No alerts have been found for Kasumi-2.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Ng HL, et al. (2026) BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(25), e17231.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. Cell, 188(2), 331.

Sadras T, et al. (2021) Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. Molecular cell, 81(10), 2094.